Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry
-
Published:2024-09
Issue:
Volume:38
Page:154-157
-
ISSN:2213-7165
-
Container-title:Journal of Global Antimicrobial Resistance
-
language:en
-
Short-container-title:Journal of Global Antimicrobial Resistance
Author:
Zhanel GeorgeORCID,
Silverman Michael,
Malhotra Janhavi,
Baxter Melanie,
Rahimi Reza,
Irfan Neal,
Girouard Gabriel,
Dhami Rita,
Kucey Melissa,
Stankus Vida,
Schmidt Kristin,
Poulin SébastienORCID,
Connors WilliamORCID,
Tascini Carlo,
Walkty Andrew,
Karlowsky James
Reference20 articles.
1. Dalbavancin, oritavancin and telavancin: a comparative review;Zhanel;Drugs,2010
2. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 Study;Karlowsky;Diag Microbiol Infect Dis,2011
3. A Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against ICU-isolated MRSA;Salem;Clin Exp Pharmacol Phys,2014
4. Escalation of antimicrobial resistance among MRSA part 1: focus on global spread;Lynch;Exp Rev Antiinfect Ther,2023
5. Escalation of antimicrobial resistance among MRSA part 2: focus on infections and treatment;Lynch;Exp Rev Antiinfect Ther,2023